Slingshot members are tracking this event:

Novartis (NVS) CANTOS to share Phase 3 data on ACZ-885 targeting inflammation to reduce cardiovascular risk on August 27th. 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cantos, Phase 3 Data, Acz-885, Cardiovascular Risk